Advertisement
Screener

Kite Pharma, Inc. Pre-Tax Income

Kite Pharma, Inc. Pre-Tax Income

Kite Pharma, Inc. reported Pre-Tax Income of -$103.06 million for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-08-08.

Discontinued › Income Statement

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2017-08-08

  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2017-06-30 was -$103.06M.
  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2017-03-31 was -$90.46M.
  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2016-12-31 was -$85.25M.
  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2016-09-30 was -$74.24M.
  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2016 was -$269.96M.
  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2015 was -$101.65M.
  • Kite Pharma, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2014 was -$42.57M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month
2017-06-30-$103.06M
10-Q · filed 2017-08-08
-$193.53M
10-Q · filed 2017-08-08
-$278.77M
derived: sum of 3 quarters · filed 2017-08-08
-$353.01M
derived: sum of 4 quarters · filed 2017-08-08
2017-03-31-$90.46M
10-Q · filed 2017-05-08
-$175.71M
derived: sum of 2 quarters · filed 2017-05-08
-$249.94M
derived: sum of 3 quarters · filed 2017-05-08
-$315.30M
derived: sum of 4 quarters · filed 2017-08-08
2016-12-31-$85.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$159.49M
derived: sum of 2 quarters · filed 2017-02-28
-$224.84M
derived: sum of 3 quarters · filed 2017-08-08
-$269.96M
10-K · filed 2017-02-28
2016-09-30-$74.24M
10-Q · filed 2016-11-09
-$139.59M
derived: sum of 2 quarters · filed 2017-08-08
-$184.72M
10-Q · filed 2016-11-09
-$222.46M
derived: sum of 4 quarters · filed 2017-08-08
2016-06-30-$65.35M
10-Q · filed 2017-08-08
-$110.48M
10-Q · filed 2017-08-08
-$148.22M
derived: sum of 3 quarters · filed 2017-08-08
-$176.15M
derived: sum of 4 quarters · filed 2017-08-08
2016-03-31-$45.13M
10-Q · filed 2017-05-08
-$82.86M
derived: sum of 2 quarters · filed 2017-05-08
-$110.80M
derived: sum of 3 quarters · filed 2017-05-08
-$131.69M
derived: sum of 4 quarters · filed 2017-05-08
2015-12-31-$37.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$65.67M
derived: sum of 2 quarters · filed 2017-02-28
-$86.56M
derived: sum of 3 quarters · filed 2017-02-28
-$101.65M
10-K · filed 2017-02-28
2015-09-30-$27.93M
10-Q · filed 2016-11-09
-$48.83M
derived: sum of 2 quarters · filed 2016-11-09
-$63.91M
10-Q · filed 2016-11-09
-$76.93M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30-$20.89M
10-Q · filed 2016-08-08
-$35.98M
10-Q · filed 2016-08-08
-$49.00M
derived: sum of 3 quarters · filed 2017-02-28
-$58.05M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31-$15.09M
10-Q · filed 2016-05-09
-$28.11M
derived: sum of 2 quarters · filed 2017-02-28
-$37.16M
derived: sum of 3 quarters · filed 2017-02-28
2014-12-31-$13.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$22.07M
derived: sum of 2 quarters · filed 2017-02-28
-$42.57M
10-K · filed 2017-02-28
2014-09-30-$9.05M
10-Q · filed 2015-11-12
-$29.55M
10-Q · filed 2015-11-12